Casdin Capital, LLC Avidity Biosciences, Inc. Transaction History
Casdin Capital, LLC
- $1.29 Billion
- Q3 2024
A detailed history of Casdin Capital, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 2,084,841 shares of RNA stock, worth $64 Million. This represents 7.44% of its overall portfolio holdings.
Number of Shares
2,084,841
Previous 2,084,841
-0.0%
Holding current value
$64 Million
Previous $85.2 Million
12.44%
% of portfolio
7.44%
Previous 7.34%
Shares
4 transactions
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$326 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$283 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$265 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$250 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$216 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.6B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...